Abcellera Biologics Inc (ABCL) Stock Price, Quote & News

Company Profile

AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a researc...

Industry: Biotechnology

Sector: Healthcare

Phone: 604 559 9005

Website: www.abcellera.com

Address:

150 W 4th Avenue, Vancouver, Canada

ispy Mar. 20 at 2:36 PM

$ABCL do we have 4.00 in us today? I feel it!

0 · Reply

DeMampCamp Mar. 20 at 2:23 PM

$ABCL Looking good so far this morning, we are absolutely at the bottom for now. The market has been trashed and we're still at $3.50ISH, bodes very, very well as we get closer to Q3 (readout). Continue to accumulate when you see fit and we'll all be very happy

1 · Reply

TradeWinner Mar. 20 at 1:46 PM

$ABCL has held up nicely through this market turmoil. Which makes sense as it’s fully funded and these market impacts have nothing to do with it. As data points near and the mkt calms down it should continue to move higher.

0 · Reply

DragonAlgo Mar. 20 at 7:50 AM

🐉 $ABCL CALL — DragonAlgo® Signal Contract: ABCL CALL Expiry: 2026-04-17 | Strike: $5.00 | Type: CALL Option Plan (premium): Entry: $0.10 Stop: $0.07 TP1: $0.13 TP2: $0.17 TP3: $0.24 🔗 https://dragonalgo.com

0 · Reply

8008track Mar. 19 at 4:43 PM

$ABCL bought more today. Little by little.

0 · Reply

EchoAnalysis8 Mar. 19 at 8:46 AM

$ABCL let me be clear 👇 I will buy on a breakout from both moving averages and will buy again in subwave 2 Wave 5 target: +207% 🚀

0 · Reply

Biker68 Mar. 18 at 7:39 PM

$ABCL That's a pretty stupid comment on a day when oil surges and the whole tech sector is down.

1 · Reply

Brb579 Mar. 18 at 3:51 PM

$ABCL its dead

0 · Reply

tradersunion353 Mar. 18 at 2:20 PM

$ABCL Another disappointing performance for people who are invested here long term to make money Adding loading friends .. its golden opportunity for you all 🤣🤣🤣

0 · Reply

Rastafari Mar. 18 at 3:08 AM

$ABCL Good summary of today’s presentation: https://m.investing.com/news/transcripts/abcellera-at-keybanc-forum-strategic-advances-in-biotech-93CH-4567110?ampMode=1

0 · Reply

AbCellera Biologics Inc. (ABCL) Presents at TD Cowen 46th Annual Health Care Conference Transcript

Feb 24, 2026, 7:27 PM EST - 23 days ago

AbCellera Biologics Inc. (ABCL) Q4 2025 Earnings Call Transcript

Feb 24, 2026, 4:05 PM EST - 23 days ago

AbCellera Reports Full Year 2025 Business Results

Feb 11, 2026, 4:05 PM EST - 5 weeks ago

AbCellera to Present at Upcoming Investor Conferences in March and April 2026

Jan 22, 2026, 4:05 PM EST - 2 months ago

AbCellera to Report Full Year 2025 Financial Results on February 24, 2026

Jan 14, 2026, 9:16 PM EST - 2 months ago

AbCellera Biologics Inc. (ABCL) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 12, 2026, 9:00 AM EST - 2 months ago

AbCellera Announces First Patients Dosed in Phase 2 Portion of its Phase 1/2 Clinical Trial of ABCL635 for the Treatment of Vasomotor Symptoms Due to Menopause

Dec 18, 2025, 9:00 AM EST - 3 months ago

AbCellera and Bruker Reach Global Settlement of Patent Litigation

Dec 8, 2025, 4:05 PM EST - 3 months ago

AbCellera to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026

Dec 8, 2025, 1:37 PM EST - 3 months ago

AbCellera Biologics Inc. (ABCL) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript

Nov 22, 2025, 12:23 AM EST - 4 months ago

AbCellera Biologics Inc. (ABCL) Presents at Jefferies London Healthcare Conference 2025 Transcript

Nov 10, 2025, 9:00 AM EST - 4 months ago

AbCellera Appoints Dr. Stephen Quake to its Board of Directors

Nov 7, 2025, 7:16 PM EST - 4 months ago

AbCellera Biologics Inc. (ABCL) Q3 2025 Earnings Call Transcript

Nov 6, 2025, 4:05 PM EST - 4 months ago

AbCellera Reports Q3 2025 Business Results

Oct 7, 2025, 4:05 PM EDT - 5 months ago

AbCellera to Participate at Upcoming Investor Conferences in November and December 2025

Oct 6, 2025, 7:35 AM EDT - 5 months ago

AbCellera Biologics: Entering Growth Phase After A Pause

Sep 29, 2025, 4:05 PM EDT - 6 months ago

AbCellera to Report Third Quarter 2025 Financial Results on November 6, 2025

Sep 10, 2025, 9:07 AM EDT - 6 months ago

AbCellera Appoints Dr. Sarah Noonberg as Chief Medical Officer

Aug 27, 2025, 9:00 AM EDT - 7 months ago

AbCellera Doses First Participants in a Phase 1 Clinical Trial of ABCL575

Aug 12, 2025, 4:05 PM EDT - 7 months ago

AbCellera to Participate at Upcoming Investor Conferences in September

Aug 7, 2025, 7:48 PM EDT - 8 months ago

AbCellera Biologics Inc. (ABCL) Q2 2025 Earnings Call Transcript

Aug 7, 2025, 4:05 PM EDT - 8 months ago

AbCellera Reports Q2 2025 Business Results & First Participants Dosed in a Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms

Jul 7, 2025, 4:05 PM EDT - 9 months ago

AbCellera to Report Second Quarter 2025 Financial Results on August 7, 2025

May 30, 2025, 1:00 PM EDT - 10 months ago

AbCellera Receives Authorization from Health Canada to Initiate a Phase 1 Clinical Trial of ABCL575

May 14, 2025, 5:00 PM EDT - 11 months ago

AbCellera Receives Authorization from Health Canada to Initiate the Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms Due to Menopause

May 12, 2025, 3:30 PM EDT - 11 months ago

AbCellera's Microfluidic Cell Culture Patent Affirmed Valid by the U.S. Court of Appeals for the Federal Circuit

May 9, 2025, 7:30 PM EDT - 11 months ago

AbCellera Presents Positive Preclinical Data on ABCL575 at the 2025 SID Annual Meeting

May 8, 2025, 10:33 PM EDT - 11 months ago

AbCellera Biologics Inc. (ABCL) Q1 2025 Earnings Call Transcript

May 8, 2025, 4:05 PM EDT - 11 months ago

AbCellera Reports Q1 2025 Business Results

Apr 29, 2025, 3:00 PM EDT - 11 months ago

AbCellera Presents Data Showing Preclinical Efficacy of PSMA x CD3 T-Cell Engagers at AACR 2025

Apr 8, 2025, 4:05 PM EDT - 1 year ago

AbCellera to Participate at Upcoming Investor Conferences in May and June

Apr 3, 2025, 4:05 PM EDT - 1 year ago

AbCellera to Report First Quarter 2025 Financial Results on May 8, 2025

Mar 25, 2025, 4:30 PM EDT - 1 year ago

AbCellera Announces Presentation of In Vivo Data on PSMA x CD3 T-Cell Engagers at AACR 2025

Feb 27, 2025, 11:26 PM EST - 1 year ago

AbCellera Biologics Inc. (ABCL) Q4 2024 Earnings Call Transcript

Feb 27, 2025, 4:05 PM EST - 1 year ago

AbCellera Reports Full Year 2024 Business Results

Feb 11, 2025, 4:05 PM EST - 1 year ago

AbCellera to Participate at Upcoming Investor Conferences in March

Jan 21, 2025, 4:05 PM EST - 1 year ago

AbCellera to Report Full Year 2024 Financial Results on February 27, 2025

Jan 13, 2025, 9:00 AM EST - 1 year ago

AbCellera Expands Collaboration with AbbVie to Develop Novel T-Cell Engagers for Oncology

Dec 23, 2024, 4:39 PM EST - 1 year ago

AbCellera Biologics: Still A Concept Stock

Nov 21, 2024, 4:05 PM EST - 1 year ago

AbCellera to Present at Upcoming Investor Conferences in December and January

Nov 7, 2024, 10:05 AM EST - 1 year ago

AbCellera Presents Data on Applications of T-Cell Engager Platform at SITC 2024

Nov 4, 2024, 7:22 PM EST - 1 year ago

AbCellera Biologics Inc. (ABCL) Q3 2024 Earnings Call Transcript

Nov 4, 2024, 4:05 PM EST - 1 year ago

AbCellera Reports Q3 2024 Business Results

Oct 22, 2024, 4:05 PM EDT - 1 year ago

AbCellera to Present at Upcoming Investor Conferences in November 2024

Oct 14, 2024, 12:04 PM EDT - 1 year ago

AbCellera: A Platform To Pipeline Transition

Oct 4, 2024, 9:00 AM EDT - 1 year ago

AbCellera Announces Presentation on T-cell Engager Platform at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2024

Sep 26, 2024, 4:05 PM EDT - 1 year ago

AbCellera to Report Third Quarter 2024 Financial Results on November 4, 2024

Aug 29, 2024, 4:05 PM EDT - 1 year ago

AbCellera to Present at Upcoming Investor Conferences in September

Aug 23, 2024, 4:43 AM EDT - 1 year ago

AbCellera: A Waiting Game With High Uncertainty

Aug 20, 2024, 9:45 AM EDT - 1 year ago

This Globant Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday

GLOB AVDX LRN PGRU

ispy Mar. 20 at 2:36 PM

$ABCL do we have 4.00 in us today? I feel it!

0 · Reply

DeMampCamp Mar. 20 at 2:23 PM

1 · Reply

TradeWinner Mar. 20 at 1:46 PM

0 · Reply

DragonAlgo Mar. 20 at 7:50 AM

0 · Reply

8008track Mar. 19 at 4:43 PM

$ABCL bought more today. Little by little.

0 · Reply

EchoAnalysis8 Mar. 19 at 8:46 AM

$ABCL let me be clear 👇 I will buy on a breakout from both moving averages and will buy again in subwave 2 Wave 5 target: +207% 🚀

0 · Reply

Biker68 Mar. 18 at 7:39 PM

$ABCL That's a pretty stupid comment on a day when oil surges and the whole tech sector is down.

1 · Reply

Brb579 Mar. 18 at 3:51 PM

$ABCL its dead

0 · Reply

tradersunion353 Mar. 18 at 2:20 PM

$ABCL Another disappointing performance for people who are invested here long term to make money Adding loading friends .. its golden opportunity for you all 🤣🤣🤣

0 · Reply

Rastafari Mar. 18 at 3:08 AM

$ABCL Good summary of today’s presentation: https://m.investing.com/news/transcripts/abcellera-at-keybanc-forum-strategic-advances-in-biotech-93CH-4567110?ampMode=1

0 · Reply

8008track Mar. 17 at 8:58 PM

$ABCL due to having internal GMP facility they don’t have to file patents right away. This allows them to file patents 2 or more years later. If you have a successful drug, then you get 2+ years of sales without any competition. This is potentially massive if they can get an approved drug.

2 · Reply

8008track Mar. 17 at 8:33 PM

$ABCL it’s go time

0 · Reply

UncleTomFlorida Mar. 17 at 4:11 PM

$ABCL https://x.com/um87777/status/2033917280514379793?s=20

0 · Reply

8008track Mar. 17 at 1:12 PM

$ABCL Anyone have a link to the live webcast? I'm looking for it and can't find it.

2 · Reply

Thelonius_Stonk Mar. 16 at 10:40 PM

$ABCL looks aight

0 · Reply

tradersunion353 Mar. 16 at 10:33 PM

$ABCL Oh great — another round of posts celebrating the noble art of buying the dip. Apparently around 90% of the discussion has nothing to do with actual returns or the stock going up… just endless updates about adding, adding, and adding more. Truly refreshing content every single time. 🙃

1 · Reply

8008track Mar. 16 at 8:13 PM

$ABCL looking forward to the presentation/discussion tomorrow. 9am ET. https://investors.abcellera.com/events/event-details/2026/KeyBanc-Capital-Markets-Healthcare-Forum-2026-laAeXoqN7Y/default.aspx

0 · Reply

TheDrunkTrader69 Mar. 16 at 6:36 PM

$ABCL looks like its going to pop, I'm still buying so a dip is good for me

0 · Reply

Determinedstocks Mar. 16 at 5:03 PM

$ABCL Treading water... I need some big dips... April

0 · Reply

DragonAlgo Mar. 16 at 12:00 PM

🐉 $ABCL CALL — DragonAlgo® Signal Contract: ABCL CALL Expiry: 2026-03-20 | Strike: $4.00 | Type: CALL Option Plan (premium): Entry: $0.05 Stop: $0.04 TP1: $0.07 TP2: $0.09 TP3: $0.12 Active momentum environment. 🔗 https://dragonalgo.com

0 · Reply

8008track Mar. 15 at 8:51 PM

$ABCL when this explodes to the upside, it will be glorious.

0 · Reply

tradersunion353 Mar. 13 at 4:32 PM

$ABCL waiting for those adding and loading comments 🤣🤣🤣. Meanwhile stock performance.. you suck

0 · Reply

Market Cap	1.07B
Revenue (ttm)	75.13M
Net Income (ttm)	-146.41M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-194.88%
Debt to Equity Ratio	0.00

Volume	2,400,100
Avg Vol	4,187,202
Day's Range	N/A - N/A
Shares Out	303.16M
Stochastic %K	56%
Beta	0.84
Analysts	Strong Sell
Price Target	$9.17